Loading... please wait
TA 220x220 - Teri Ardleigh

Teri Ardleigh

Leadership Council Member

Teri Ardleigh’s Biotechnology career began in 2002.  She Co-Founded Xcovery Vision in 2010 which focuses on Ophthalmology.  Xcovery Vision is a drug discovery company currently developing an oral pill for Adult Macular Degeneration (AMD) – the current therapy for this disease is an injection into the eye.  She has experience working with many biotechnology companies and many different aspects of the process, marketing, licensing, and corporate development; working with small and large companies alike, both nationally and internationally.

Prior to joining Xcovery Vision in 2010, Ms. Ardleigh held the position of Vice President of Corporate Development at MolecularMD a diagnostic company and Vice President of Business Development at Xcovery, an oncology drug development company.  She was responsible for start-up requirements, identifying markets, and creating strong relationships to keep up with the latest medical advancements in the industry.

Ms. Ardleigh has also started her own graphic design and marketing company in the past.  The focus of Ardleigh Associates was to prepare the sales force for clients to create value with the proper messaging.  Logos and branding were accomplished for several academic, for profit, and nonprofit companies during its operations.

Teri was an alternate member of the United States Equestrian Grand Prix Team for the Munich Olympic Games.  She was the first to win 20 gold medals in the USET class and train at the Olympic headquarters as a junior rider.

For over 10 years she has been an active participant in many groups and associations. These groups include: Foundation Fighting Blindness, The Association for Research in Vision and Ophthalmology, and BIO International.

Teri’s priority in the biotechnology industry is finding cures for different medical conditions that affect our society. Her passions and involvement shapes her understanding of the corporate needs of cost effectiveness during fund-raising modes.  Teri also serves as an instrument to patients in providing high-end research and drug developments without lowering the standards and quality of products offered.